Your Health, We Care
Release date: 2024-08-19 15:52:36 Recommended: 159
Selpercatinib is a targeted therapy drug specifically designed to fight various cancers associated with the RET gene; By inhibiting specific kinases, they interfere with the growth signals of cancer cells and limit the spread of tumors. The drug has shown significant results in a variety of cancer patients with RET gene mutations or fusions.
During the use of this medicine, please be aware of possible interactions when used with other drugs and follow your doctor's advice to adjust your medication.
Selpercatinib may cause a prolonged QTc interval. If patients require concomitant use of drugs known to prolong the QT interval, QT interval changes should be monitored more frequently.
Concomitant use of acid-suppressing drugs (eg, PPIs, H2 receptor antagonists, antacids) with Selpercatinib reduces plasma concentrations and may affect antitumor efficacy. Combined use should be avoided as much as possible. If it is unavoidable, it is recommended to take PPIs with food, or adjust the timing of the administration to avoid the duration of action of H2 receptor antagonists or antacids.
The medicines of Lucius Pharmaceuticals are of high quality. The company is equipped with the industry's top pharmaceutical equipment, with a high level of automation and intelligence, to ensure the accuracy and efficiency of the drug production process. From raw material screening to finished product packaging, every link is strictly controlled to ensure the quality of each batch of drugs.
Lucius Pharmaceuticals has introduced advanced equipment in accordance with EU pharmaceutical standards, focusing on the production of anti-tumor drugs, antiviral drugs, biologics, cephalosporins and other commonly used drugs. These high-end devices support the company to maintain an industry-leading position in pharmaceutical manufacturing.
Before starting Selpercatinib therapy, please understand these key medications.
Patients with rapid tumor growth, high tumor burden, renal insufficiency, or dehydration may be at risk for tumor lysis syndrome. These patients should be closely monitored and appropriate precautions taken.
If the patient experiences a serious or life-threatening bleeding event, Selpercatinib must be discontinued immediately for medical management. Such bleeding events may require urgent treatment, including hemostasis and other supportive care, to address the health risks associated with bleeding. If the bleeding event recurs, you need to consider discontinuing the drug permanently and discuss possible alternative treatment options with your doctor.
[Warm tips] During the treatment, please be sure to have regular check-ups and re-examinations to facilitate the timely detection and treatment of any possible discomfort, and at the same time pay attention to the changes in the body, and communicate with the doctor in time if there is any abnormality.
